Latest Gabather News & Updates

See the latest news and media coverage for Gabather. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gabather

Pharmaceutical company developing CNS therapeutics

gabather.com

Headquarters: Södertälje, Sweden
Founded year: 2014
Company type: Public company
Number of employees: 4–10
Industry: Pharmaceuticals

Last updated May 29

Latest news about Gabather

In short: Gabather launched Phase II TOTEMS study of GT-002 and reported narrower Q2 losses.

Company announcements

May 29 Gabather

Gabather publishes Q1 2026 interim report

The company conducts a directed issue of SEK 4.2 million and initiates the TOTEMS patient study for drug candidate GT-002.

February 27 Gabather

Gabather publishes annual report for 2025

The company achieved positive cash flow and strengthened its capital structure through new share issues, with planned clinical start in Q1 2026.

November 27, 2025 Gabather

Gabather presents interim report for Q3 2025

The report shows a loss and an adjusted timeline for the TOTEMS study. CFO resigned.

September 1, 2025 Gabather

Gabather releases interim report for H1 2025 with delayed clinical trials and financing plans

The company reports zero revenue and an operating result of -1.6 MSEK. The TOTEMS study is postponed to Q4 2025 due to quality issues, while new financing alternatives are being evaluated.

Media coverage

May 7 Life Sciences Sweden

Gabather in collaboration with Danish hospital - starts schizophrenia study

The Södertälje company Gabather will for the first time test effect on cognition in schizophrenia in patients with its most advanced drug candidate.

March 18 BioStock

Gabather carries out a directed new share issue of SEK 4,2 million - Biostock

Gabather is conducting a directed new share issue of approximately SEK 4,2 million with the aim of strengthening the balance sheet and current working capital...

February 12, 2024 Seeking Alpha

Gabather reports initial positive results from the EEG/fMRI target engagement study

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study...

February 12, 2024 Seeking Alpha

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

STOCKHOLM, April 10, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the...

Never miss news about Gabather

Track Gabather and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gabather competitors & trending companies

Browse news for competitors to Gabather and other trending companies.